Fit by company stage
Veeva is the right answer for pharma companies that need a system of record across clinical, regulatory, and quality at scale. If you are preparing one IND with a team of eight, Veeva is the wrong size — the budget alone is off by an order of magnitude. Regfo is stage-appropriate: you onboard in an afternoon, get cited gap findings in seconds, and pay under $1,000/mo while you grow.
Regfo
Designed for Series A–C biotech — priced and sized for that stage.
Veeva Systems
Designed for commercial pharma — priced for that scale.
Where AI shows up
Veeva markets Veeva AI as agentic AI built natively into the Vault platform, with agents rolling out across commercial, quality, regulatory, clinical, safety, and medical through 2025–2026. So this is not a "they do not have AI" comparison. The real difference is focus: Regfo was built from day one as a preclinical-to-IND compliance engine for drugs and biologics — the extraction, rule matching, and paragraph-level citation logic are the whole product. As of mid-2026 Veeva does not market a dedicated feature for that specific preclinical-IND gap-analysis workflow.
Regfo
Purpose-built for preclinical-IND gap analysis — citations are the core output.
Veeva Systems
Veeva AI built into Vault, with agents rolling out across modules through 2026.
Time and cost to adopt
A Veeva deployment takes quarters and involves system integrators and validation work. For an emerging biotech with an IND timeline, neither the time nor the cost is available. Regfo onboards in minutes and bills monthly. When the company grows to scale and Veeva becomes the right platform, the compliance work already done in Regfo transfers as document outputs.
Regfo
Free ($0), Pro ($399/mo), Team ($999/mo). 20% off annual. No setup fees, no implementation contracts.
Veeva Systems
Enterprise SaaS timelines — typical first-go-live six to twelve months out.